Philipp Geyer, Ph.D. of OmicEra on high-throughput clinical proteomics and applications to COVID-19

The blood plasma proteome has a huge potential for the discovery of novel biomarkers that can be applied to assess human health and disease stages. Learn about corner stones of high-throughput proteomics such as lab automation and a robust MS system such as the Bruker timsTOF Pro, which enables the analysis of thousands of plasma samples. We further argue to apply contamination marker panels to evaluate potential biomarker candidates and to analyze large-scale or longitudinal sample sets to deal with biological variation of the proteome. We exemplify the possibility to identify new biomarkers by investigating a longitudinal cohort of COVID-19 patients.

Run time: 14:41 mins

Philipp Geyer, Ph.D. of OmicEra on High-throughput clinical proteomics and applications to COVID-19

Video Credit: Bruker Life Sciences Mass Spectrometry

Other Videos by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.